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Effects of an Antisense Oligonucleotide Inhibitor of C-Reactive Protein
Synthesis on the Endotoxin Challenge Response in Healthy Human
Male Volunteers
Robert Noveck, MD, PhD; Erik S. G. Stroes, MD, PhD; JoAnn D. Flaim, PhD; Brenda F. Baker, PhD; Steve Hughes, MD; Mark J. Graham, MSc;
Rosanne M. Crooke, PhD; Paul M Ridker, MD, MPH
Background-—C-reactive protein (CRP) binds to damaged cells, activates the classical complement pathway, is elevated in multiple
inﬂammatory conditions, and provides prognostic information on risk of future atherosclerotic events. It is controversial, however,
as to whether inhibiting CRP synthesis would have any direct anti-inﬂammatory effects in humans.
Methods and Results-—A placebo-controlled study was used to evaluate the effects of ISIS 329993 (ISIS-CRPRx) on the acute-
phase response after endotoxin challenge in 30 evaluable subjects. Healthy adult males were randomly allocated to receive 6
injections over a 22-day period of placebo or active therapy with ISIS 329993 at 400- or 600-mg doses. Eligible subjects were
subsequently challenged with a bolus of endotoxin (2 ng/kg). Inﬂammatory and hematological biomarkers were measured before
and serially after the challenge. ISIS-CRPRx was well tolerated with no serious adverse events. Median CRP levels increased more
than 50-fold from baseline 24 hours after endotoxin challenge in the placebo group. In contrast, the median increase in CRP levels
was attenuated by 37% (400 mg) and 69% (600 mg) in subjects pretreated with ISIS-CRPRx (P<0.05 vs. placebo). All other aspects
of the acute inﬂammatory response were similar between treatment groups.
Conclusion-—Pretreatment of subjects with ISIS-CRPRx selectively reduced the endotoxin-induced increase in CRP levels in a
dose-dependent manner, without affecting other components of the acute-phase response. These data demonstrate the speciﬁcity
of antisense oligonucleotides and provide an investigative tool to further deﬁne the role of CRP in human pathological conditions.
( J Am Heart Assoc. 2014;3:e001084 doi: 10.1161/JAHA.114.001084)
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C reactive protein (CRP) is an acute-phase reactantsynthesized primarily by hepatocytes.1,2 Plasma CRP
levels are normally <3 mg/L, but can increase by over 1000-
fold in response to inﬂammatory stimuli. Induction of CRP
expression occurs at the transcriptional level through
cytokine signaling, predominantly interleukin-6 (IL-6).2,3
Human CRP binds to damaged cells and can activate the
classical complement pathway, augmenting inﬂammation and
furthering tissue damage.4 Moreover, CRP is elevated in many
chronic inﬂammatory disorders and has consistently been
shown to provide prognostic information on the risk of future
vascular events that is comparable in magnitude to that
provided by elevations of cholesterol and blood pressure.5–7 It
is controversial, however, as to whether CRP in healthy
subjects has direct proinﬂammatory effects, because ﬁndings
from infusion studies using bacterial recombinant CRP8–10
have not been replicated in studies using pharmaceutical-
grade human CRP.11
ISIS 329993 (ISIS-CRPRx) is an antisense oligonucleotide
(ASO) drug, complementary to the coding region of the human
CRP messenger RNA (mRNA). ISIS-CRPRx is a second-gener-
ation ASO drug 20 nucleotides in length comprised of a
phosphorothioate backbone, a central 20-deoxyribose region
to support the recruitment of the ubiquitous ribonucleolytic
enzyme, RNase H, and 20-O-methoxyethyl modiﬁcations in the
30 and 50 ﬂanking regions to enhance binding afﬁnity for the
target mRNA and drug half-life.12–15 Watson-Crick base-pair
association, and subsequent elicitation of RNase H activity by
ISIS-CRPRx, leads to degradation of the human CRP mRNA
transcript to effectively block its translation.16
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Initial preclinical studies of CRP antisense inhibitors
demonstrated pharmacological activity at both the mRNA
and protein levels in transgenic (Tg) mouse models, as well as
in monkeys challenged with IL-6.17 Subsequent investigations
found that antisense reduction of CRP with ISIS-CRPRx in CRP
Tg mice with established collagen-induced arthritis signiﬁ-
cantly improved clinical signs of disease.18 In humans, single
and multiple doses of ISIS-CRPRx from 50 to 600 mg were
safe and well-tolerated in the initial phase I study involving
healthy volunteers. In addition to these ﬁndings, serum CRP
levels were reduced from 54% to 83% from baseline in a small
cohort of subjects with elevated baseline CRP levels who
received 5 doses intravenously of 600 mg of ISIS-CRPRx over
a 3-week treatment period.18
Puriﬁed endotoxin, a cell wall component of Gram-
negative bacteria, has been extensively used as a model to
study acute inﬂammatory response in humans. After an
intravenous bolus of endotoxin, there is a well-characterized
response that consists of mild ﬂu-like symptoms, hemato-
logical changes, marked increases in cytokines and acute-
phase proteins, as well as activation of coagulation and
complement pathways.19–22 We thus sought to determine
the effect of the novel antisense CRP inhibitor, ISIS-CRPRx,
on the acute-phase response induced by an endotoxin
challenge.
Methods
Study Design
We conducted a phase I, double-blind, placebo-controlled,
adaptive, dose-response study to evaluate the effects of ISIS-
CRPRx on the acute-phase response to endotoxin challenge in
healthy volunteers. The study consisted of a 28-day screening
period, a 22-day treatment period, a 5-day endotoxin
challenge period, and a 63-day safety follow-up period
(Figure 1). Study subjects were enrolled into 2 sequential
dose cohorts, each randomized at a 2:1 ratio, active to
placebo, in order to achieve 10 evaluable subjects per
treatment arm. The ﬁrst dose cohort was 400 mg of ISIS-
CRPRx, or placebo. The dose for the second cohort (600 mg)
was decided by a data monitoring committee based on the
results from the treatment period and endotoxin challenge of
the ﬁrst cohort. All subjects, monitors, study center person-
nel, and the sponsor were blinded during the course of the
study, except the pharmacist, who prepared the study drug.
The protocol was approved by an independent institutional
review board (Copernicus Group, Durham, NC), and the study
was performed in compliance with the standards of good
clinical practice and the Declaration of Helsinki in its revised
edition (Washington, DC, 2002).
Study Participants
Eligible subjects were male volunteers (18 to 40 years in age
and 55 to 95 kg in body weight) who were in good health
and without clinically signiﬁcant abnormalities in their
medical history, physical examination or laboratory evalua-
tions. The study excluded subjects who had a CRP level
>10 mg/L, were current smokers, had a history of any
clinically important allergy or a known allergy to lactose or
polyethylene glycol (PEG; excipients in the endotoxin formu-
lation), were currently using any medication or health
supplement, received a vaccination within 6 months of
screening, participated in a clinical trial of an immunosup-
pressive drug or one using endotoxin within 6 months of
screening, had received another investigational drug, medical
device, or medical procedure within 90 days or 5 half-lives of
screening, or participated in an investigational study involv-
ing systemic administration of an oligonucleotide within
9 months of screening. Subjects were enrolled at a single
site in the United States (Duke University Medical Center,
Durham, NC) from April 23, 2012 to August 9, 2012. All
participants gave written informed consent before enroll-
ment. The last subject completed the safety follow-up period
on December 6, 2012.
D1
-D28
R
2:1
Treatment
Screening
Endotoxin
Challenge Safety Follow-Up
D3 D5 D8 D15 D22
D26
LPS
2 ng/kg
Figure 1. Study schedule. *Subjects who participated in the endotoxin challenge were admitted to the
study center on day 25 for 3 overnight stays. On day 26, subjects received an intravenous bolus of
Escherichia coli lipopolysaccharide (LPS) at 2 ng/kg body weight. Arrow symbols indicate study drug dosing
days; D, day; IV, intravenous; R, randomization.
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Study Drug
ISIS 329993 was supplied in 2-mL stoppered glass vials as a
1-mL solution (200 mg/mL) for single use only by Isis
Pharmaceuticals, Inc. (Carlsbad, CA). Placebo was 0.9% sterile
saline. Study drug was administered by a 2-hour intravenous
infusion.
Treatment Period
Eligible subjects were admitted to the study center on day 1
for 5 consecutive overnight stays. Study drug was adminis-
tered on days 1, 3, and 5. Subjects were discharged on day 5
after all study procedures were completed. Subjects returned
to the study center for an overnight stay on days 7, 14, and
21. Study drug was administered on days 8, 15, and 22.
Subjects were discharged after drug administration and
completion of all study procedures. Safety and clinical
laboratory evaluations were performed periodically through-
out the treatment period, and adverse events (AEs) were
recorded.
Endotoxin
Endotoxin was supplied as a sterile, white, lyophilized powder
in a clear glass, aluminum-sealed, stoppered 5-mL vial. Each
vial contained 10 000 EU (1 lg) of lyophilized reference
endotoxin, 10 mg of lactose, and 1 mg of PEG 6000, which
was reconstituted with 5 mL of sterile, preservative-free
water to a ﬁnal concentration of 200 ng/mL.
Reference Endotoxin is a puriﬁed lipopolysaccharide
prepared from Escherichia coli O:113 (U.S. Reference Stan-
dard Endotoxin; Clinical Center reference endotoxin, Lot 3)
under good manufacturing practice guidelines by the Phar-
macy Development Service, Clinical Center, National Insti-
tutes of Health (NIH; Bethesda, MD). This material has been
approved by the U.S. Food and Drug Administration for
investigational use only.
Endotoxin Challenge
Subjects were admitted to the study center on day 25 and
examined for evidence of infection or any other condition that
precluded participation in the endotoxin challenge. Assess-
ments included vital signs, 12-lead electrocardiogram (ECG),
clinical laboratory tests, urinalysis, and a drug/alcohol screen.
On day 26, eligible subjects received an intravenous bolus
of reconstituted reference endotoxin in the amount of 2 ng/
kg body weight. Vital signs were recorded with subjects at
rest in an approximate 45-degree supine position before and
at various time points after administration of the endotoxin
bolus. Blood samples were also collected before and after
endotoxin challenge for assessment of known markers of the
acute-phase response. Markers evaluated included those for
inﬂammation (tumor necrosis factor alpha [TNF-a], IL-1b, IL-6,
monocyte chemoattractant protein 1 [MCP-1], CRP, serum
amyloid A [SAA], ﬁbrinogen, soluble E-selectin, and lipopoly-
saccharide [LPS]-binding protein), complement activation (Bb,
C5a, and C4), coagulation (prothrombin [PT] fragment [F1+2],
thrombin-antithrombin complex, and endogenous thrombin
potential), and ﬁbrinolysis (D-dimer). On day 27, after
collecting the 24-hour postendotoxin samples, subjects
underwent safety assessments (vital signs, safety labs, ECG,
AE check, and a brief physical examination). Subjects were
discharged from the facility on day 28 after the 48-hour
postendotoxin samples were drawn. On day 29, subjects
returned to the study center for collection of 72-hour
postendotoxin samples, vital signs, and AEs.
Safety Follow-Up Period
Subjects were followed until day 92. During this time,
subjects returned to the study center on days 43 (7 days)
and 92 (7 days) for safety and clinical laboratory evalua-
tions. Any AEs were recorded.
Lifestyle Restrictions
Alcohol consumption was not permitted from days 3
through 29. Subjects also refrained from alcohol consumption
for 48 hours before their follow-up visits to the study center
on study days 43 and 92. Subjects were required to fast for at
least 6 hours before all safety laboratory samples were
collected.
For the endotoxin challenge, subjects were required to
refrain from consuming food or drinks containing caffeine,
including tea, coffee, chocolate, and carbonated drinks, from
48 hours before check-in on days 25 through 29. Subjects
were not permitted sunbathing or any physical exercise,
sports, or exertion other than normal walking within 72 hours
before study days 25 through 29.
Concomitant Medications
The use of prescription and over-the-counter medications
(with the exception of occasional acetaminophen) was
prohibited during this study, unless the occurrence of an AE
required a drug therapy.
Any antibiotic use within 30 days before the endotoxin
challenge on day 26 was prohibited. Subjects were not
permitted any prescribed medication or any other over-the-
counter medication, health/herbal supplement, or vitamin by
any route of administration within 7 days of study day 26, or
5 half-lives of the drug, whichever was longer. Subjects
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requiring any medication concurrent with the study were not
eligible for participation.
Medications used to manage the expected clinical effects
from endotoxin, including headache and fever, may blunt the
cytokine response. To evaluate the potential of cytokine
responses, prescribed medication was used only if nonphar-
macological approaches were insufﬁcient to manage emer-
gent symptoms.
Safety Monitoring
Safety and tolerability were assessed by determining the
incidence, severity, and dose relationship of AEs and changes
in laboratory parameters.
Laboratory Analysis
Standard laboratory tests were performed by LabCorp
(Research Triangle Park, NC). CRP was measured with a
high-sensitivity assay by MedPace Reference Labs (Cincinnati,
OH), complement factors by National Jewish Health (Denver,
CO), inﬂammation markers by Aushon (Billerica, MA), and
coagulation markers by the Hemostasis and Thrombosis
Center at Duke University Medical Center (Durham, NC).
Data Analysis
The safety population consisted of all subjects who received
at least 1 dose of study drug. Analysis of the response to
endotoxin challenge was performed on the per-protocol
population. This population consisted of all subjects who
completed dosing, received the endotoxin challenge, and had
at least 1 postendotoxin challenge CRP value.
Subjects assigned to placebo were pooled and analyzed as
a group. Baseline was deﬁned as the last evaluation preceding
the ﬁrst dose of study drug, unless speciﬁed otherwise.
Statistical tests were 2-sided with a type I error rate
controlled at an alpha level of 0.05. Statistical signiﬁcance
was determined using Wilcoxon’s rank-sum test based on
sample size and data distribution. Analysis of data was
performed using SAS software (version 9.2; SAS Institute Inc.,
Cary, NC).
Results
Subjects
Forty-two eligible adult males were enrolled into the study in
order to achieve 10 evaluable subjects per treatment arm.
Subjects were assigned sequentially to 1 of 2 dose cohorts at
a 2:1 randomization ratio of active to placebo. The ﬁrst cohort
assigned was for treatment with a 400-mg dose and the
second was for treatment with a 600-mg dose. A total of 35 of
42 subjects were dosed with study drug or placebo before the
endotoxin challenge (23 active and 12 placebo). Baseline
characteristics of subjects who received at least 1 dose of
study drug are summarized by treatment group in Table 1.
Thirty-three of 35 (94%) treated subjects received each of
the 6 scheduled doses of study drug. One subject assigned to
placebo discontinued after receiving 4 doses because of a low
white blood cell (WBC) count, and 1 subject withdrew consent
after receiving 5 doses of 600 mg of ISIS-CRPRx. Two subjects
withdrew consent after receiving the 6 doses of study drug
(n=1, placebo; n=1, 400 mg of ISIS-CRPRx) and consequently
did not participate in the endotoxin challenge. Thirty of 31
subjects who participated in the endotoxin challenge (10
subjects per treatment assignment) were evaluable for
analysis of the effects of treatment on the response to
endotoxin challenge. A complete representation of the ﬂow of
study participants is shown in Figure 2.
Safety and AEs in the Treatment Period Preceding
Endotoxin Challenge
ISIS-CRPRx was well tolerated at both doses tested. Reported
AEs were, if anything, more common in the pooled placebo
group during the treatment period (12 events in 13 partic-
ipants) than in the 2 ISIS-CRPRx-treated groups (10 events in
23 participants). AEs were predominantly associated with
intravenous infusion of study drug. These AEs occurred
in both placebo and ISIS-CRPRx-treated subjects (Table 2). In
addition to these events, 3 of 23 (13%) subjects dosed with
ISIS-CRPRx reported headache. Otherwise, no unexpected
safety concerns occurred in association with study drug
during this period. There were no unexplained or clinically
remarkable changes in routine laboratory measures, nor was
there a signiﬁcant change in CRP levels from baseline to the
end of treatment between dose groups (data not shown).
Table 1. Subject Demographics and Baseline Characteristics
Placebo (N=12) 400 mg (N=12) 600 mg (N=11)
Race, n (%)
White 7 (58) 6 (50) 4 (36)
Black 4 (33) 6 (50) 6 (55)
Other 1 (8) 0 (0) 1 (9)
Age, y 22.73.7 28.76.5 27.75.8
Weight, kg 78.810.5 77.29.8 80.411.4
BMI, kg/m2 25.52.6 24.82.9 25.23.1
CRP, mg/L 0.85 (0.30, 1.15) 0.60 (0.55, 1.40) 0.50 (0.20, 1.10)
Values represent the meanSD for age, weight, and BMI; and the median (Q1, Q3) for
CRP. BMI indicates body mass index; CRP, C-reactive protein.
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Endotoxin Challenge
Pretreatment of subjects with ISIS-CRPRx produced a dose-
dependent, statistically signiﬁcant reduction in endotoxin-
induced CRP levels (Figures 3 and 4), as well as the area
under the curve over time. Speciﬁcally, among those allocated
to placebo, median CRP levels increased more than 50-fold
from baseline 24 hours after endotoxin challenge. By con-
trast, the median increase in CRP levels was attenuated by
37% (400 mg) and 69% (600 mg) in subjects pretreated with
ISIS-CRPRx (P<0.05 vs. placebo; Figure 3B). Maximum CRP
levels remained below 10 mg/L in 8 of 10 subjects in the
600-mg dose group. There was no effect, however, from CRP
antisense treatment on induction of SAA expression (Fig-
ure 3C). Similarly, there was no effect on upstream induction
of proinﬂammatory cytokines and chemokines, including TNF-
a, IL-6, and MCP-1 (Figure 5). Endotoxin-induced activation of
the coagulation cascade, ﬁbrinolytic pathway, and endothe-
lium was also unaffected by pretreatment with ISIS-CRPRx,
relative to placebo, as measured by changes in D-dimer, PT
fragment (F1+2), and soluble E-selectin levels (Figure 6).
Similarly, there was no differential effect between treatment
groups on complement factors or split products, C4, Bb, and
C5a (Figure 7).
Expected endotoxin-induced changes in blood cell counts
were similar in subjects pretreated with ISIS-CRPRx, compared
to placebo-pretreated subjects. As expected, total WBC
116 Screened 
42  
Randomized 
12 Dosed 
 12 Completed 
14  400 mg 13 Placebo 
74 Failed Screen 
        58 Eligibility Criteria 
        10 Withdrew Consent 
          6 Other 
12 Safety Analysis 
10 PD Analysis 
12 Safety Analysis 
10 PD Analysis 
1 withdrew consent 
11 Dosed 
    1 Discontinued 
 1 withdrew consent 
 10 Completed 
15  600 mg 
12 Dosed 
        1 Discontinued  
 1 abnormal lab test 
      11 Completed 
11 Safety Analysis 
10 PD Analysis 
6 Ineligible (Day -1) 
2 : 1 
 11 Follow-up 
       2 Discontinued  
           1 withdrew consent 
           1 lost in f/u 
       9 Completed 
 12 Follow-up 
       4 Discontinued  
           2 withdrew consent 
           2 lost in f/u 
       8 Completed 
 12 Follow-up 
       3 Discontinued  
           1 withdrew consent 
           2 lost in f/u 
       9 Completed 
11 Endotoxin Challenge 
1 Withdrew consent 
10 Completed 
10 Endotoxin Challenge 
10 Completed 
10 Endotoxin Challenge 
10 Completed 
1 withdrew consent 1 withdrew consent 
Figure 2. Flow of study participants. PD indicates pharmacodynamic.
Table 2. Adverse Events Reported During Treatment Period
(Days 1 Through 25/ET, Safety Population)
Preferred MedDRA
Term, n (%)
Placebo
(N=12)
400 mg
(N=12)
600 mg
(N=11)
Headache 0 (0) 1 (8) 2 (18)
Infusion site hematoma 1 (8) 0 (0) 2 (18)
Infusion site
extravasation
1 (8) 0 (0) 1 (9)
Infusion site pain 2 (17) 0 (0) 0 (0)
Pain in extremity 0 (0) 1 (8) 0 (0)
Dermatitis contact 0 (0) 1 (8) 0 (0)
Gastroenteritis 0 (0) 1 (8) 0 (0)
Abdominal pain 0 (0) 0 (0) 1 (9)
Infusion-related
reaction
1 (8) 0 (0) 0 (0)
WBC count decreased 1 (8) 0 (0) 0 (0)
ET indicates endotoxin; WBC, white blood cell.
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counts initially decreased postchallenge, reaching a nadir
after 1 hour, and then increased above baseline to counts,
ranging from 7100 to 17 500 cells/mm3 at 8 hours. The
associated subtype proﬁles, marked by concordant lympho-
and monocytopenia, were also unaltered by pretreatment with
ISIS-CRPRx, relative to placebo, based on both the absolute
and differential counts. Affected parameters returned toward
baseline values by 24 hours after the challenge.
The physiological response to endotoxin challenge was
similar across treatment groups, as reﬂected by changes from
baseline in body temperature, heart rate, and blood pressure
during the 72-hour postchallenge period (Figure 8). Increases
in median body temperature peaked 3.5 hours post–endotoxin
challenge. Maximum increases in individual subjects ranged
from 0.5 to 2.1°C. Heart rates increased sharply 1 hour after
endotoxin exposure, peaking 3 to 4 hours postchallenge, with
maximum increases from baseline in individual subjects of
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Figure 3. Pretreatment with ISIS-CRPRx attenuated endotoxin-
induced increase in CRP levels in a dose-dependent and selective
manner. (A) Maximum change in CRP levels by subject, (B) median
change in CRP levels over time by treatment group, and
(C) median change in SAA over time by treatment group, relative
to preendotoxin baseline levels. CRP indicates C-reactive protein;
IQR, interquartile range; SAA, serum amyloid A.
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Figure 4. Absolute CRP concentrations pre– and post–endo-
toxin challenge in (A) treatment groups, (B) placebo-treated
subjects, (C) 400-mg ISIS-CRPRx-treated subjects, and (D) 600-mg
ISIS-CRPRx-treated subjects. CRP indicates C-reactive protein;
IQR, interquartile range.
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18 to 69 beats per minute. Subjects’ heart rates gradually
returned toward baseline by 12 to 24 hours after the challenge.
A transient increase in systolic and diastolic blood pressure
also occurred in all treatment groups, with median values
peaking at the 1.5 hour time point. Maximum increases from
baseline in systolic and diastolic pressure by subject ranged
from 2 to 32 and 1 to 31 mm Hg, respectively. For all
physiological parameters, no remarkable differences were
observed after endotoxin challenge for those pretreated with
ISIS-CRPRx, as compared to placebo.
Classical endotoxin-induced ﬂu-like symptoms (eg, head-
ache, fever, and chills) were reported by 30 of 30 (100%)
should be subject’s, that is, irrespective of treatment group
(Table 3). All symptoms resolved spontaneously without
sequelae. Other routine laboratory measures, such as liver
transaminases, were unremarkable.
Follow-up Period
Subjects were monitored for 63 days after the endotoxin
challenge or otherwise after the last dose of study drug.
Twenty-six of 35 (74%) subjects completed the follow-up
period (Figure 2). Three AEs were reported during this period,
2 in the placebo group and 1 in the 600-mg dose group
(Table 4). The latter event was characterized as a mild
increase in creatinine, as measured on the last visit, day 92
(1.29 mg/dL, upper limit of normal=1.27), and then con-
ﬁrmed 7 days later (1.35 mg/dL). The subjects’ blood urea
A
B
C
-10
0
10
20
30
40
50
60
70
80
90
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 T
N
Fα
 (p
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
0 1 2 3 4 8 12 16 24 36 48 72
Placebo 400 MG 600 MG
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 IL
6 
(n
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
-1
0
1
2
3
4
5
0 1 2 3 4 8 12 16 24 36 48 72
Placebo 400 MG 600 MG
-10
10
30
50
70
90
110
130
150
0 1 2 3 4 8 12 16 24 36 48 72
Placebo 400 MG 600 MG
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 M
C
P1
 (n
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
Figure 5. ISIS-CRPRx pretreatment had no effect on endotoxin-
induced increases in cytokine and chemokine levels. Median
changes in (A) TNF-a, (B) IL-6, and (C) MCP-1, over time by
treatment group. IL indicates interleukin; IQR, interquartile range;
MCP-1, monocyte chemoattractant protein 1; TNF-a, tumor
necrosis factor alpha.
A
B
C
-100
100
300
500
700
900
1100
1300
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 D
-d
im
er
 (n
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
0 1 2 3 4 8 12 16 24 36 48 72
Placebo 400 MG 600 MG
-200
300
800
1300
1800
2300
2800
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 P
ro
th
ro
m
bi
n 
Fr
ag
m
en
t (
F1
+2
) (
pm
ol
/L
),
(M
ed
ia
n 
± 
IQ
R
)
0 1 2 3 4 8 12 16 24 36 48 72
Placebo 400 MG 600 MG
-10
40
90
140
190
240
Post-Endotoxin Challenge, (hours)
0 1 2 3 4 8 12 16 24 36 48 72
C
ha
ng
e 
in
 E
Se
le
ct
in
 (n
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
Placebo 400 MG 600 MG
Figure 6. ISIS-CRPRx pretreatment had no effect on endotoxin-
induced changes in coagulation parameters. Median changes in
(A) D-dimer, (B) prothrombin fragment [F1+2], and (C) E-selectin,
over time by treatment group. IQR indicates interquartile range.
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nitrogen (BUN) concentration, BUN/creatinine ratio, and
serum potassium concentration were within the range of
normal. Serum creatinine levels returned to normal within
3 weeks.
Discussion
In this phase I, double-blind, placebo-controlled study con-
ducted in healthy volunteers, we observed that the ASO, ISIS-
CRPRx, selectively attenuated the endotoxin-induced increase
in CRP levels in a dose-dependent manner. Other signals and
processes of the acute response to endotoxin challenge
remained intact, however, including the transient increases in
cytokines and chemokines levels, activation of both the
coagulation cascade and ﬁbrinolytic process, ﬂuctuations in
WBC counts and differentials, increased body temperature
and heart rate, as well as anticipated clinical signs and
B
C
A
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
0 1 2 3 4 8 12 16 24 36 48 72
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 C
om
pl
em
en
t B
b 
(μ
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
Placebo 400 MG 600 MG
-2
-1
0
1
2
3
4
5
0 1 2 3 4 8 12 16 24 36 48 72
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 C
om
pl
em
en
t C
5a
 (n
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
Placebo 400 MG 600 MG
-3
-2
-1
0
1
2
3
4
5
6
Placebo 400 MG 600 MG
0 1 2 3 4 8 12 16 24 36 48 72
Post-Endotoxin Challenge, (hours)
C
ha
ng
e 
in
 C
om
pl
em
en
t C
4 
(m
g/
m
L)
,
(M
ed
ia
n 
± 
IQ
R
)
Figure 7. ISIS-CRPRx pretreatment had no effect on endotoxin-
induced changes in complement factors. Median change in (A)
complement C4, (B) complement split product Bb, and (C)
complement split product C5a, over time by treatment group. IQR
indicates interquartile range.
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Figure 8. ISIS-CRPRx pretreatment had no effect on endotoxin-
induced changes in vital signs. Median changes in (A) body
temperature, (B) heart rate, (C) systolic blood pressure, and
(D) diastolic blood pressure, over time by treatment group. IQR
indicates interquartile range.
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symptoms. Overall, ISIS-CRPRx was well tolerated and with
no evident safety issues during the treatment period at both
the 400- and 600-mg doses tested.
We believe our data to be of clinical as well as
pathophysiological interest for several reasons. First, these
data provide a robust demonstration of the high degree of
selectivity and speciﬁcity that can be achieved by antisense
technology. In this regard, the observed dose-dependent
effects of ISIS-CRPRx on CRP synthesis without alteration of
other acute-phase parameters provides in vivo conﬁrmation
of ISIS-CRPRx as an ASO designed speciﬁcally to accelerate
degradation of human CRP mRNA without inducing other
secondary effects.
Second, our data lend further support to the concept that
pentameric CRP is predominantly a biomarker of disease,
rather than a causal factor, in the pathophysiology of inﬂam-
mation. Endotoxin infusion led to the anticipated increases in
cytokine and chemokine expression, and leukocytosis,
whereas the secondary increase in CRP had no effect on these
parameters. Thus, in spite of a 3-fold decrease in CRP peak at
24 hours in the antisense-treated group, compared to placebo,
none of the parameters reﬂecting inﬂammation, coagulation, or
complement activation revealed any difference in the time
frame between 24 and 48 hours. These data do not support the
concept that pentameric CRP itself has a direct, active effect
on these pathways in otherwise healthy individuals. In fact,
these results complement recent work from Lane et al.,11
showing that infusion of pharmaceutical-grade CRP had little
effect on the induction of inﬂammation itself, again in healthy
individuals. The current data are also consistent with Mende-
lian randomization studies that have found CRP to be a
predictor of vascular events, but unlikely in itself to be in a
critical causal pathway. However, these data are not informa-
tive about the potential role of monomeric CRP in these
processes.23
Neither the current results nor those of Lane et al.11
reduce the clinical utility of CRP as a biomarker of inﬂamma-
tion or as a predictor of future vascular risk. However, the
neutral results of both studies do emphasize the importance
of targeting upstream mediators of inﬂammation as potential
treatments for vascular disease, rather than a downstream
biomarker, such as CRP itself.24 In this regard, 2 large-scale
trials directly testing the inﬂammation hypothesis of athero-
thrombosis are underway, including the 10 000 participant
Canakinumab Anti-Inﬂammatory Thrombosis Outcomes Study
(CANTOS) targeting upstream IL-1b production25 and the
7000 patient NIH-sponsored Cardiovascular Inﬂammation
Reduction Trial (CIRT) testing low-dose methotrexate.26,27
Whereas both canakinumab and low-dose methotrexate
reduce downstream CRP, they do so by also inhibiting the
function and/or expression of upstream IL-6. This is likely to
be biologically relevant because Mendelian randomization
studies similar to those that have been neutral for CRP are
strongly positive for IL-6 signaling. Speciﬁcally, 2 studies have
now been presented indicating that polymorphism in the IL-6
receptor pathway associates with lifelong reductions in CRP
and lifelong reductions in rates of vascular events.28,29 Data
from the CANTOS and CIRT hard outcome vascular prevention
trials are anticipated within the next 3 to 4 years.
Finally, the unique speciﬁcity of ISIS-CRPRx provides a new
investigative tool for those interested in CRP function in a
variety of settings. For example, the ability to dose-titrate
inhibition of CRP synthesis may provide a method to reduce
the AEs of complement-induced CRP damage known to occur
in the setting of tissue damage. To our knowledge, the only
Table 3. Adverse Events Reported During Endotoxin
Challenge Period (Days 26 to 29)
Preferred MedDRA Term,
n (%)
Placebo
(N=10)
400 mg
(N=11)
600 mg
(N=10)
Headache 8 (80) 10 (91) 10 (100)
Pyrexia 8 (80) 9 (82) 9 (90)
Chills 8 (80) 9 (82) 8 (80)
Myalgia 6 (60) 7 (64) 5 (50)
Nausea 3 (30) 5 (45) 4 (40)
Tachycardia 5 (50) 3 (27) 2 (20)
Vomiting 2 (20) 0 (0) 1 (10)
Dizziness 2 (20) 1 (9) 0 (0.0)
Palpitations 0 (0) 1 (9) 1 (10)
Fatigue 0 (0) 1 (9) 1 (10)
Catheter site pain 0 (0) 1 (9) 0 (0)
Flushing 0 (0) 1 (9) 0 (0)
Hyperhidrosis 0 (0) 1 (9) 0 (0)
Photophobia 0 (0) 0 (0) 1 (10)
Hypotension 1 (10) 0 (0) 0 (0)
Lethargy 1 (10) 0 (0) 0 (0)
Musculoskeletal pain 1 (10) 0 (0) 0 (0)
Cyanosis 1 (10) 0 (0) 0 (0)
Livedo reticularis 1 (10) 0 (0) 0 (0)
Table 4. Adverse Events Reported During Follow-up Period
(Day 30/ET to End of Study, Safety Population)
Preferred MedDRA Term,
n (%)
Placebo
(N=12)
400 mg
(N=12)
600 mg
(N=11)
Blood creatinine
increased
0 (0) 0 (0) 1 (9)
Headache 1 (8) 0 (0) 0 (0)
Sinus headache 1 (8) 0 (0) 0 (0)
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other inhibitor of CRP uses a small-molecule approach to bind
and interfere with the acute-phase protein’s function in vivo.30
However, the respective small molecule evaluated in the
reported animal model studies is no longer being considered
for development in the clinic (http://pentraxin.word-
press.com/rd-programs/).
Limitations of our study merit consideration. First, we
studied only men, and thus our data cannot be generalized to
women. Issues such as hormone use are known to increase
CRP production. Second, endotoxin challenge models are a
robust acute induction of the innate immune response and
may mask, or not effectively model, any potential aberrant
functions and processes associated with abnormally elevated
CRP levels. Third, the effects of CRP inhibition in healthy
volunteers challenged with endotoxin may not reﬂect effects
that occur in subjects burdened with disease, a chronic
pathological condition, or acute cell damage. Finally, it is
theoretically possible that ISIS-CRPrx did not affect secondary
cytokine and chemokine expression because the net 69%
reduction in the 600-mg dose might have been insufﬁcient.
We think this unlikely because many individuals had CRP
reductions of 85% to 90%, and these individuals also did not
demonstrate secondary cytokine or chemokine changes.
Nonetheless, whether complete inhibition of CRP synthesis
might have this effect cannot be fully addressed here.
Alternative approaches, such as RNAi therapeutics, might be
able to provide such levels of inhibition, as has recently been
shown for proprotein convertase subtilisin/kexin type 9.31
However, most RNAi therapeutics are formulated in lipid
nanoparticle (LNP) delivery systems to overcome stability and
delivery limitations. Because LNPs themselves may elicit
signiﬁcant proinﬂammatory cytokine and gene expression
effects and can produce infusion-related reactions,32 patients
receiving RNAi therapeutics typically require premedication
with dexamethasone, nonsteroidal anti-inﬂammatory drugs,
and antihistamines, which have the potential to confound
effects on the inﬂammatory pathways being interrogated
here.31,33 Second-generation ASO approaches that do not
require liposomal encapsulation might provide a direction for
future research, particularly because the predominant site of
CRP synthesis are hepatocytes.
In conclusion, in this placebo-controlled study, we demon-
strate that pretreatment of healthy young men with ISIS-
CRPRx selectively reduces the endotoxin-induced increase in
CRP levels in a dose-dependent manner, but does not inhibit
other components of the classical acute-phase response.
These data demonstrate the speciﬁcity of ASOs and provide
an investigative tool to further deﬁne the role of CRP in human
pathological conditions. For example, it will be of interest to
know if the ASO approach outlined here alters the dissocia-
tion between pentameric CRP to monomeric CRP, particularly
in settings with ongoing inﬂammation.
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